NASDAQ:SBFM Sunshine Biopharma Q4 2025 Earnings Report $0.84 -0.03 (-3.63%) As of 10:53 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sunshine Biopharma EPS ResultsActual EPS-$4.60Consensus EPS -$2.70Beat/MissMissed by -$1.90One Year Ago EPSN/ASunshine Biopharma Revenue ResultsActual Revenue$8.58 millionExpected Revenue$10.00 millionBeat/MissMissed by -$1.42 millionYoY Revenue GrowthN/ASunshine Biopharma Announcement DetailsQuarterQ4 2025Date4/3/2026TimeDuring Market HoursConference Call DateN/AConference Call TimeN/AUpcoming EarningsSunshine Biopharma's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Sunshine Biopharma Earnings HeadlinesA Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest OpportunityAugust 26, 2026 | markets.businessinsider.comEXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug ApprovalAugust 4, 2026 | benzinga.comThe Pentagon Has 120 Days to Solve This Critical Mineral ProblemChina controls roughly 80% of the world's tungsten supply, and new Pentagon sourcing restrictions take effect January 1. The U.S. hasn't mined tungsten domestically since 2015. A little-known Nasdaq company controls Severniy Katpar, one of the largest undeveloped tungsten deposits, with potential to supply 15% of global demand. Two U.S. agencies have floated up to $1.6 billion in financing support as tungsten prices climb as much as 900%.September 24 at 1:00 AM | The Tomorrow Investor (Ad)Sunshine Biopharma Inc.: Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and VomitingJuly 30, 2026 | finanznachrichten.deSunshine Biopharma Inc.: Sunshine Biopharma and University of Arizona Publish Significant New Research FindingsJuly 20, 2026 | finanznachrichten.deSBFM Share News TodayMay 15, 2026 | uk.investing.comSee More Sunshine Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sunshine Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sunshine Biopharma and other key companies, straight to your email. Email Address About Sunshine BiopharmaSunshine Biopharma (NASDAQ:SBFM) (NASDAQ:SBFM) is a pharmaceutical and biotechnology company focused on the development of therapies for cancer and other serious diseases. Its research and development activities are centered on proprietary drug candidates intended to address unmet medical needs. The company’s lead oncology candidate is Adva-27a, a small-molecule topoisomerase II inhibitor being investigated for potential use against advanced solid tumors, including certain cancers that may be resistant to existing treatments. Sunshine Biopharma has also described research involving mRNA-based therapeutic approaches and treatments targeting coronaviruses. In addition to its biotechnology pipeline, Sunshine Biopharma has pursued pharmaceutical commercialization activities in Canada through its Canadian operations, which are associated with the distribution and sale of prescription and over-the-counter products. The company is headquartered in Montreal, Quebec, and has been led by founder and Chief Executive Officer Dr. Steve N. Slilaty.View Sunshine Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
